FDA Approves New Interchangeable Biosimilar to Perjeta

On November 13, the FDA approved pertuzumab-dpzb as an interchangeable biosimilar to pertuzumab. This is the first approval of a biosimilar for pertuzumab.

For more information, read the FDA announcement and visit the Shanghai Henlius Biologics website.

Posted on 11/14/2025